Navigation Links
New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes

* Significant blood sugar reductions seen across range of patient populations, including varied ethnic groups, the elderly, and those at high risk of developing diabetes

* Galvus lowers blood sugar when added to a sulfonylurea, reinforcing efficacy in combination with commonly used diabetes medicines

* Data confirm good tolerability in humans with studies showing incidence of side effects similar to placebo in monotherapy trials

* European regulatory decision anticipated by end 2007; discussions continue on steps to gain US approval

BASEL, Switzerland, June 25, 2007 - Galvus® (vildagliptin), a new once-daily oral treatment for type 2 diabetes submitted for approval in the US and Europe, has been shown in new clinical data to deliver consistent and robust blood sugar reductions in patients with this progressive disease estimated to affect about 246 million people worldwide[1].

The findings, presented at the 67th Annual Scientific Sessions of the American Diabetes Association (ADA), are consistent with earlier results demonstrating the efficacy and tolerability of Galvus both as a monotherapy and when added to many commonly used diabetes medicines in a range of patients across the type 2 diabetes disease spectrum[2],[3],[4]. These include varied ethnic groups[3] and the elderly[4] as well as patients with impaired glucose tolerance at high risk of developing diabetes[5] and those with uncontrolled blood sugar levels[6].

"These results further reinforce the clinical benefits of Galvus as an important new treatment option for patients with type 2 diabetes," said James Shannon, MD, Global Head of Development at Novartis Pharma AG. "We remain convinced that Galvus is safe and effective and will continue to work with health authorities to ensure this medicine can be made available to patients worldwide as soon as possible."

A member of a new class of diabetes medici
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
9. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
10. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
11. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks

Post Your Comments:
(Date:11/21/2009)..., , WASHINGTON, Nov. 21 An ur...ectious diseases in the developing world has promp...mic researchers, non-profit product development pa...ology companies. As noted today in a symposium at ... Tropical Medicine and Hygiene (ASTMH), these coll...
(Date:11/20/2009)..., , CARY, N.C., Nov. 20 /PRNewswire-FirstCa...X ), a specialty pharmaceutical company focused on...cant products primarily for the respiratory and re... a Warning Letter from the Food and Drug Administr...le tablets (Phenylephrine HCl 10 mg, Pyrilamine Ma...
(Date:11/20/2009)..., , HARRISBURG, Pa., Nov. 20 /PRNewswire-U... providing free H1N1 flu shots to members of prior...e vaccine. ,, A total of 18 clinics are being h... are from 2 p.m. to 8 p.m. Hours on Saturday, Nov....the clinics will operate from 2 p.m. to 8 p.m. ,...
Breaking Medicine Technology:ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries 2ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries 3Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal 2Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal 3Pennsylvania Department of Health Begins Statewide H1N1 Vaccination Clinics Targeting Priority Populations; Some Appointments Still Available 2Fate Therapeutics announces creation of small molecule platform for commercial scale reprogramming 10409 1Fate Therapeutics announces creation of small molecule platform for commercial scale reprogramming 10409 2Project Runway Designer in Philadelphia for AIDS Walk Philly to Educate About Living with HIV through Living Positive By Design 59703 1Project Runway Designer in Philadelphia for AIDS Walk Philly to Educate About Living with HIV through Living Positive By Design 59703 2Project Runway Designer in Philadelphia for AIDS Walk Philly to Educate About Living with HIV through Living Positive By Design 59703 3Florida Celebrates National Healthcare Quality Week 59698 1Florida Celebrates National Healthcare Quality Week 59698 2
...ANDS, Texas--(BUSINESS WIRE)--Jun 21, 2007 - Opexa...ved in the,development and commercialization of ce...ta in an open-label Phase I/II,extension clinical ...in(TM), for multiple sclerosis (MS). In this one-y...ng remitting (RRMS),and secondary progressive (SPM...
...ISCO & NEW DELHI, India--(BUSINESS WIRE)--Jun ...-based non-profit,pharmaceutical company, today an... approved drug product, Paromomycin IM,Injection (...f The,New England Journal of Medicine (NEJM). This...n is safe, effective, and well suited,to curing vi...
Other Medicine Technology:Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 2Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 3Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 4Opexa Therapeutics Reports Positive Top-line Data in Phase I/II,Extension Trial with Tovaxin for Multiple Sclerosis 5Research on New Treatment for Neglected Disease Published in The,New England Journal of Medicine 2Research on New Treatment for Neglected Disease Published in The,New England Journal of Medicine 3Research on New Treatment for Neglected Disease Published in The,New England Journal of Medicine 4
(Date:11/22/2009)... World Famous Lasik surgeo...k surgery to an ART in his pursuit for vision beyo...es an international clientel and is widely publish... Jacksonville, FL (PRWEB) November ...nstitute has been selected by Goldline Research a...
(Date:11/22/2009)... NEW YORK (Nov. 22 2009) -- Physician-scientists f...a molecular mechanism that may prove to be a power...homa, a type of cancer that affects lymphocytes, o... researchers have been able to powerfully suppress...ls. , Promising results have led to the design o...
(Date:11/22/2009)... HealthSmart, an innovativ...unced that it has successfully completed a recapit...Company’s other lenders. Silver Point Capit...enwich, Connecticut. This recapitalization allows...its business strategy. , , ...
(Date:11/22/2009)..., , WASHINGTON, Nov. 21 /PRNewswire-USNewswir...ollowing statement upon the United States Senate,s...ealth Care legislation: ,, "Senators Arlen Spec...ians and all Pennsylvanians for casting stand-up, ...sident Obama,s historic Affordable Health Care Ref...
(Date:11/21/2009)..., , "This bill provides for an unpreced... is health care about if it is not for preserving ...ded, it must be defeated." Charmaine Yoest ,...mericans United for Life Action President and CEO ... the Senate by releasing the following statement: ...
Breaking Medicine News(10 mins):Health News:Dr. Arun Gulani Listed in Forbes Magazine as One of The Leading Laser Eye Surgeons of the United States 2Health News:New cancer target for non-Hodgkin's lymphoma 2Health News:HealthSmart Completes Recapitalization to Support Continued Growth, Daniel D. Crowley Named Chairman 2Health News:Leading Anti-Abortion Group Vows to Vigorously Fight the Senate Health Bill 2
...HINGTON (30 May 2008) -- Legislation that IEEE-USA...ination in employment and health insurance based o.... , The Genetic Information Nondiscrimination Act...appreciation in a letter ( http://www.ieeeusa.org/...
...el Votes, 16-0, in Favor of Short-Term Treatment o...), CHICAGO, May 30 GlaxoSmithKline (NYSE: GSK )...rug Administration,s,Oncology Drugs Advisory Commi...ents with chronic idiopathic,thrombocytopenic purp...
... prevalence of pre-cancerous masses in the colon i... 49 years of age and those who are 50 to 59 years ... the official journal of the American Gastroentero...easing incidence of colon cancer at that age. Beca...
...RK, May 30 We know the damage the sun can do to,o...damaging rays?, Listen to this report from Transi...R.aspx?story=35173 , Registered journalists can a...aphics and,photos for free and unrestricted use at...
..., Calif., May 30 Edwards Lifesciences,Corporation...nologies to,treat advanced cardiovascular disease,...ons from the U.S. Food and Drug Administration (FD...pertain to preclinical bench testing and the clari...
...HESTER, Minn. -- Mayo Clinic researchers have deve...f two prominent tumor suppressor genes, p16 and p1... these genes were expressed at increased levels as...ging, while p19 stops that process. , The finding...
Other Medicine News:Health News:IEEE-USA-supported Genetic Information Nondiscrimination Act signed into law 2Health News:PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL 2Health News:PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL 3Health News:PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL 4Health News:Prevalence of pre-cancerous masses in the colon same in patients in their 40s and 50s 2Health News:Prevalence of pre-cancerous masses in the colon same in patients in their 40s and 50s 3Health News:Edwards Lifesciences Receives Additional Questions From the FDA About the LifeStent Product Line 2
...nlike any trocar system you've ever seen., ,The O...ms in one designed to be versatile, operationally...eeds., ,By offering options in disposability and ...effectively address the individual preferences of ...
ENDOPATH Surgical Thoracic Trocar Sleeve with Rounded Tip Obturator
MultAcoice™ Metzenbaum Curved Scissors
MultAcoice™ Dissecting Scissors
Medicine Products: